During the past decade, Massachusetts General Hospital, Neuroendocrine Unit conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 3 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 2 clinical trials were completed. i.e. 200% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Massachusetts General Hospital, Neuroendocrine Unit" are "Cushings Disease" (2 trials), "Acromegaly" (1 trials), "Breast Cancer" (1 trials), "Central Diabetes Insipidus" (1 trials) and "Cushing Disease" (1 trials). Many other conditions were trialed in "Massachusetts General Hospital, Neuroendocrine Unit" in a lesser frequency.

Most popular intervention types in "Massachusetts General Hospital, Neuroendocrine Unit" are "Drug" (5 trials). Other intervention types were less common.

The name of intervention was led by "Alpelisib" (1 trials), "BIM 23A760" (1 trials), "Fulvestrant" (1 trials), "Goserelin" (1 trials) and "LCI699" (1 trials). Other intervention names were less common.

The vast majority of trials in "Massachusetts General Hospital, Neuroendocrine Unit" are 5 trials for "All" genders.

Currently, there are NaN active trials in "Massachusetts General Hospital, Neuroendocrine Unit". 1 are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Massachusetts General Hospital, Neuroendocrine Unit, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Massachusetts General Hospital, Neuroendocrine Unit, 1 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".